Karolinska Competitors

Stocks . Sweden . 
Stock . Karolinska Development AB
KDEV Stock  SEK 0.29  0.00  0.00%   
The company operates in Pharmaceuticals space and is part of Health Care industry. Peers for Karolinska Development include IRLAB Therapeutics, Lipum AB, Isofol Medical, Bio Works, and Annexin Pharmaceuticals and others in the group. Peer context helps frame relative positioning. Use this module to test if Karolinska Development has durable advantages versus sector peers.

Pair Correlation for Karolinska Development and AlzeCure Pharma Snapshot

Weak diversification

The correlation between KDEV and ALZCUR is 0.3, which Macroaxis classifies as Weak diversification for the selected horizon. The overlap area represents the portion of risk that may be diversified away when both instruments are held together and nothing else in the portfolio changes.

Moving against Karolinska Stock

  0.71SHB-B Svenska HandelsbankenPairCorr
  0.69SWED-A Swedbank ABPairCorr
  0.67SHB-A Svenska HandelsbankenPairCorr
  0.64VOLV-A AB VolvoPairCorr
  0.64VOLV-B AB VolvoPairCorr
The degree to which Karolinska Development's exhibits mean reversion depends on how efficiently the market prices new information. In highly covered equities, the mean reversion window tends to be shorter.
Hype
Prediction
LowEstimatedHigh
0.010.296.89
Details
Intrinsic
Valuation
LowRealHigh
0.010.286.88
Details
Naive
Forecast
LowNextHigh
0.010.306.90
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.270.290.31
Details
Before investing in Karolinska Development, assess how Karolinska Development's compares to its competitive peer group. A company that appears undervalued in absolute terms may be fairly priced when measured against sector-relative benchmarks.

Karolinska Development Competition Correlation Matrix

Correlation analysis between Karolinska Development AB and its competitors helps investors understand whether diversification is real or only superficial inside the same peer group. This matrix is most informative when investors want to know whether adding another peer would improve diversification, increase crowding, or leave total risk largely unchanged.

High positive correlations

ANNX
+ 0.79
IRLAB-A
BOUL
+ 0.79
IRLAB-A
ISOFOL
+ 0.76
LIPUM
LIPUM
+ 0.65
IRLAB-A
ALZCUR
+ 0.64
ANNX
BOUL
+ 0.63
LIPUM
  

High negative correlations

ALZCUR
- 0.71
BIOWKS
ANNX
- 0.62
BIOWKS
BIOWKS
- 0.59
IRLAB-A
BOUL
- 0.55
BIOWKS
BIOWKS
- 0.55
LIPUM
BIOWKS
- 0.29
ISOFOL

Risk-Adjusted Indicators

There is a big difference between Karolinska Stock performing well and Karolinska Development Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Karolinska Development's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Karolinska Development Competitive Analysis

Karolinska Development competitive analysis is a powerful tool for investors seeking to contextualize Karolinska Development's financial performance. Comparing Karolinska Development's key ratios to peers highlights areas where the company excels or needs improvement.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
KDEV IRLAB-A LIPUM ISOFOL BIOWKS ANNX INIT BOUL MNTC ALZCUR
 0.00 
0.29
Karolinska
 1.23 
1.60
IRLAB
 0.35 
14.35
Lipum
 2.99 
0.69
Isofol
 2.84 
3.08
Bio
 1.40 
14.50
Annexin
 3.01 
2.90
Initiator
 2.71 
3.95
Boule
 3.11 
14.00
Mentice
 1.55 
1.90
AlzeCure
Market Volatility
(90 Days Market Risk)
Stable
Very High
Very Low
Abnormal
Very High
Slightly Elevated
Stable
Elevated
Stable
Very High
Market Performance
(90 Days Performance)
Soft
Weak
Weak
Soft
Balanced
Weak
Weak
Weak
Soft
Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
High
Low
Low
High
Average
High
Low
Low
High
Risky
Current Valuation
(Equity Enterprise Value)
Fairly Valued
Over Valued
Fairly Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Analysis
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Hold
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Current Ratio
0.24
9.19
N/A
1.21
9.14
9.56
N/A
1.3
N/A
48.05
Net Asset
1.11 B
472.45 M
49.66 M
401.36 M
120.86 M
52.79 M
53.7 M
572.03 M
261.9 M
45.65 M
Profit Margin
N/A
-1.69
N/A
N/A
-1.31
N/A
N/A
0.0232
-0.14
N/A
EBITDA
177.79 M
55.62 M
-52.11 M
-198.49 M
-8.6 M
-50.28 M
-23.06 M
55.69 M
-776 K
-77.2 M
Operating Margin
-14.44
-1.68
117.68
-13.09
-1.27
N/A
N/A
0.0527
-0.12
N/A
Current Valuation
247.24 M
1.74 B
98.1 M
-42.41 M
635.01 M
125.48 M
256.25 M
562.26 M
2.09 B
173.51 M
Price To Book
0.37
6.24
35.65
0.65
8.03
4.9
5.64
1.06
13.94
6.62
Retained Earnings
-1.85 B
N/A
N/A
N/A
N/A
N/A
N/A
-6 M
N/A
N/A
Current Asset
259 M
N/A
N/A
N/A
N/A
N/A
N/A
135 M
N/A
N/A
Five Year Return
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.73
N/A
N/A
Beta
0.4
0.16
N/A
1.56
0.99
1.55
0.76
0.58
1.24
0.76
Number Of Employees
7
31
5
15
36
4
3
200
122
14
Shares Outstanding
267.28 M
51.79 M
7.65 M
161.52 M
34.87 M
154.5 M
52.36 M
38.83 M
25.57 M
59.19 M
Cash Flow From Operations
16.7 M
128.64 M
-34.3 M
-188.43 M
-13.37 M
-45.02 M
-34.1 M
43.28 M
-5.13 M
-70.64 M
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.028
N/A
N/A
Total Debt
N/A
3.57 M
1.57 M
110 K
N/A
N/A
13.29 M
50.6 M
N/A
N/A
Return On Equity
-0.11
-0.28
-1.81
-0.69
-0.66
-1.06
-1.05
0.0335
-0.2
-1.55
Z Score
-1.4
88.2
36.3
N/A
N/A
N/A
14.4
6.0
N/A
-3.3
Return On Asset
-0.0168
-0.15
-0.91
-0.36
-0.35
-0.57
-0.49
0.0271
-0.0553
-0.78
Book Value Per Share
4.56
6.25
0.59
1.14
2.55
0.2
0.71
11.91
6.36
0.63
Current Liabilities
9 M
N/A
N/A
N/A
N/A
N/A
N/A
70 M
N/A
N/A
Total Asset
1.11 B
472.45 M
49.66 M
401.36 M
120.86 M
52.79 M
53.7 M
572.03 M
261.9 M
45.65 M
Debt To Equity
177.8
2.9
N/A
0.048
N/A
1.2
N/A
46.0
N/A
N/A
Target Price
4.5
200.0
22.0
1.31
27.0
2.0
18.29
87.0
54.0
11.88
Shares Owned By Institutions
5.97
22.49
8.14
12.47
5.59
5.06
0.46
27.69
38.18
6.48
Market Capitalization
510.26 M
525.71 M
104.07 M
109.18 M
718.4 M
189.95 M
319.34 M
532.01 M
1.44 B
254.44 M
Price To Earning
7.42
N/A
N/A
N/A
N/A
N/A
N/A
24.26
N/A
N/A
Price To Sales
204.27
33.49
3380.24
7.45
19.71
N/A
N/A
0.68
4.56
N/A
Net Income
170.82 M
51.78 M
-52.26 M
-200.25 M
-12.94 M
-52.14 M
-21.06 M
23.27 M
-29.19 M
-77.78 M
Earnings Per Share
0.86
0.81
-10.77
-1.42
-0.41
-0.43
-0.79
0.96
-0.98
-1.78
Shares Owned By Insiders
37.17
38.63
81.67
25.71
54.85
45.17
N/A
12.65
43.87
41.31
Revenue
2.17 M
207.78 M
N/A
22.41 M
21.91 M
N/A
N/A
463.34 M
185.06 M
N/A
Working Capital
250 M
N/A
N/A
N/A
N/A
N/A
N/A
65 M
N/A
N/A
Cash And Equivalents
42.4 M
401.9 M
N/A
379.45 M
46.35 M
22.77 M
N/A
38.18 M
N/A
222.05 M
Cash Per Share
1.85
2.89
N/A
0.93
2.4
1.29
N/A
0.87
N/A
5.88
Gross Profit
2.17 M
126.05 M
-48.69 M
-174.31 M
53.01 M
N/A
-21.63 M
227.9 M
188.94 M
N/A
Day Typical Price
0.29
1.62
14.35
0.69
3.02
14.43
2.89
3.99
14.07
1.94
Accumulation Distribution
N/A
0.0539
N/A
0.0429
18393.91
0.0274
5254.62
0.0295
0.0141
0.0547
Market Facilitation Index
N/A
0.09
N/A
0.03
0.0
0.4
0.0
0.12
0.2
0.11
Daily Balance Of Power
0.0
-0.22
9.2 T
0.6667
-0.24
0.5
-0.41
-0.92
-2.25
-0.27
Period Momentum Indicator
N/A
-0.02
0.05
0.02
-0.09
0.2
-0.09
-0.11
-0.45
-0.03
Rate Of Daily Change
1.0
0.99
1.0
1.03
0.97
1.01
0.97
0.97
0.97
0.98
Day Median Price
0.29
1.63
14.35
0.69
2.99
14.4
2.88
4.01
14.1
1.95
Price Action Indicator
N/A
-0.04
0.025
0.015
0.045
0.2
-0.03
-0.11
-0.32
-0.07
Relative Strength Index
47.19
40.2
52.97
50.41
57.01
42.32
45.71
37.47
50.18
43.5
Coefficient Of Variation
-807.80
-1,091
-1,641
83214.58
901.88
-1,180
1975.28
-657.63
-4,504
-20,601
Mean Deviation
4.52
2.7
0.7248
2.77
2.96
4.18
2.3
2.92
2.22
3.2
Jensen Alpha
-1.06
-0.34
-0.07
-0.0032
0.4235
-0.57
0.1614
-0.57
-0.08
-0.03
Total Risk Alpha
-1.06
-0.34
-0.07
-0.0015
0.4251
-0.57
0.1624
-0.57
-0.08
-0.03
Sortino Ratio
N/A
N/A
N/A
-0.0008
0.1307
N/A
0.057
N/A
N/A
N/A
Downside Variance
N/A
N/A
N/A
14.09
10.53
N/A
8.03
N/A
N/A
N/A
Standard Deviation
8.47
3.62
1.02
5.56
3.91
6.61
3.38
3.68
3.08
4.54
Kurtosis
12.38
0.4602
1.39
31.79
1.22
10.05
2.17
-0.30
1.53
0.8895
Potential Upside
11.54
6.51
1.75
2.99
8.89
9.04
6.47
4.0
5.24
9.55
Treynor Ratio
1.19
0.5567
-0.18
-0.01
-0.39
3.02
0.617
2.52
-0.20
-0.17
Maximum Drawdown
47.86
18.07
5.07
50.92
16.66
44.62
19.49
15.09
13.16
21.85
Variance
71.74
13.11
1.04
30.9
15.31
43.66
11.45
13.52
9.49
20.61
Market Risk Adjusted Performance
1.2
0.5667
-0.17
0.0044
-0.38
3.03
0.627
2.53
-0.19
-0.16
Risk Adjusted Performance
-0.09
-0.06
-0.04
0.0095
0.0941
-0.06
0.047
-0.11
-0.01
0.0045
Skewness
-1.01
0.0875
0.4955
4.57
0.972
2.14
0.7844
-0.06
0.762
0.4822
Semi Deviation
N/A
N/A
N/A
3.13
2.74
N/A
2.58
N/A
N/A
N/A
Information Ratio
-0.12
-0.09
-0.07
-0.0006
0.1084
-0.09
0.0477
-0.15
-0.03
-0.01
Value At Risk
-13.16
-6.47
-1.69
-4.17
-4.50
-8.94
-5.63
-6.67
-4.91
-6.38
Expected Short fall
N/A
N/A
N/A
-4.16
-3.69
N/A
-3.21
N/A
N/A
N/A
Downside Deviation
N/A
N/A
N/A
3.75
3.24
N/A
2.83
N/A
N/A
N/A
Semi Variance
N/A
N/A
N/A
9.82
7.53
N/A
6.65
N/A
N/A
N/A

Karolinska Development Peer Performance Charts

How to Analyze Karolinska Development Against Peers

Karolinska Development's peer analysis compares Karolinska Development with related companies to put valuation, quality, and risk metrics in context. This helps determine whether recent performance is company-specific or broadly sector-driven. A practical workflow includes:
  • Set a relevant peer group: Include direct competitors and close alternatives with comparable business exposure.
  • Benchmark core financials: Compare profitability, growth, capital structure, and cash flow quality.
  • Check valuation dispersion: Review whether Karolinska Development trades at a premium or discount versus peers and why.
  • Evaluate risk profile: Compare volatility, drawdowns, and correlation to avoid false diversification assumptions.
  • Document the thesis: Record where Karolinska Development leads or lags and what catalysts could close or widen the gap.
Use this as an educational baseline, then validate conclusions with current filings, market conditions, and portfolio objectives.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY